Seres Therapeutics, Inc. (MCRB) vs NanoViricides, Inc. (NNVC)

Seres Therapeutics, Inc. and NanoViricides, Inc. are both Biotechnology companies. Seres Therapeutics, Inc. and NanoViricides, Inc. are of similar size ($38.0M and $36.0M). NanoViricides, Inc. has the higher net margin (0.00% vs −1,192.9%) and the higher return on invested capital (−86.0% vs −277.3%). Across the 13 metrics below, NanoViricides, Inc. leads on 9 and Seres Therapeutics, Inc. on 4.

Valuation

Metric MCRB NNVC Biotechnology median
P/E n/m n/m 7.88
P/S 18.14 n/m 11.47
P/B 0.99 3.40 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 64.29 n/m 10.73
Earnings yield (69.03%) (29.86%) (28.84%)
Free cash flow yield (150.01%) (23.69%) (23.03%)

Profitability

Metric MCRB NNVC Biotechnology median
Gross margin 100.00% 0.00% 65.16%
Operating margin (4,462.77%) 0.00% 0.00%
Net margin (1,192.94%) 0.00% 0.00%
Free cash flow margin (2,721.83%) 0.00% 0.00%
Return on equity (66.57%) (89.97%) (57.72%)
Return on assets (18.31%) (79.91%) (49.22%)
Return on invested capital (277.30%) (86.02%) 0.00%

Growth

Metric MCRB NNVC Biotechnology median
Revenue growth (TTM) (98.51%) — 5.64%
EPS growth (last fiscal year) 0.00% 10.00% —
Revenue growth, 5-year CAGR (53.03%) — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric MCRB NNVC Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 2.11 3.17 4.73
Net debt to EBITDA 0.51 0.18 0.96

Dividend

Metric MCRB NNVC Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric MCRB NNVC Biotechnology median
Market cap 35.99m 38.04m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack